01:59 PM EDT, 04/02/2025 (MT Newswires) -- Labcorp ( LH ) said Wednesday it launched a blood-based biomarker test called pTau-217/Beta Amyloid 42 Ratio to aid in the diagnosis of Alzheimer's disease.

The blood test confirm the presence of amyloid pathology, which is associated with the disease, the company said.

Labcorp ( LH ) said the test offers a sensitivity and specificity of 95%, which is "substantially equivalent" to the performance of amyloid positron emission tomography imaging and cerebrospinal fluid testing.

The test can be used in clinical trials in addition to clinical patient care, the company said.

Price: 236.59, Change: +3.94, Percent Change: +1.69